Aimmune Therapeutics (NASDAQ:AIMT) had its target price upped by investment analysts at Piper Jaffray Companies from $38.00 to $60.00 in a research note issued on Tuesday. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Piper Jaffray Companies’ price target points to a potential upside of 65.75% from the stock’s current price.

AIMT has been the subject of a number of other reports. BidaskClub cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Credit Suisse Group lifted their price target on Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a report on Monday, October 23rd. ValuEngine lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday. Zacks Investment Research upgraded Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price objective for the company in a research report on Wednesday, November 8th. Finally, Wedbush reiterated an “outperform” rating and issued a $70.00 price objective on shares of Aimmune Therapeutics in a research report on Friday. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $53.80.

Aimmune Therapeutics (AIMT) opened at $36.20 on Tuesday. Aimmune Therapeutics has a twelve month low of $15.97 and a twelve month high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.09. equities analysts forecast that Aimmune Therapeutics will post -2.57 EPS for the current fiscal year.

In other news, CEO Stephen George Dilly sold 1,154 shares of the business’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $26.24, for a total transaction of $30,280.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Douglas T. Sheehy sold 3,750 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $37.00, for a total value of $138,750.00. Following the transaction, the insider now owns 3,750 shares of the company’s stock, valued at $138,750. The disclosure for this sale can be found here. Over the last quarter, insiders sold 321,470 shares of company stock valued at $8,538,994. Corporate insiders own 17.59% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. grew its position in shares of Aimmune Therapeutics by 5.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 87,057 shares of the biotechnology company’s stock worth $1,892,000 after buying an additional 4,788 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Aimmune Therapeutics during the 2nd quarter worth about $442,000. Goldman Sachs Group Inc. grew its position in shares of Aimmune Therapeutics by 139.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company’s stock worth $4,675,000 after buying an additional 132,603 shares during the period. Bank of New York Mellon Corp grew its position in shares of Aimmune Therapeutics by 16.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 131,353 shares of the biotechnology company’s stock worth $2,700,000 after buying an additional 19,016 shares during the period. Finally, Citadel Advisors LLC acquired a new position in shares of Aimmune Therapeutics during the 2nd quarter worth about $360,000. Institutional investors own 73.34% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Aimmune Therapeutics (AIMT) PT Raised to $60.00” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/12/05/aimmune-therapeutics-aimt-pt-raised-to-60-00.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.